SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000891293-22-000026
Filing Date
2022-05-12
Accepted
2022-05-12 16:31:17
Documents
44
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q ctic-20220331.htm   iXBRL 10-Q 770322
2 EX-31.1 ex311-ceo302q1fy22.htm EX-31.1 11334
3 EX-31.2 ex312-cfo302q1fy22.htm EX-31.2 12202
4 EX-32 ex32-ceocfo906q1fy22.htm EX-32 11647
  Complete submission text file 0000891293-22-000026.txt   3610386

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ctic-20220331.xsd EX-101.SCH 27523
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT ctic-20220331_cal.xml EX-101.CAL 41870
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT ctic-20220331_def.xml EX-101.DEF 155459
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ctic-20220331_lab.xml EX-101.LAB 352210
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ctic-20220331_pre.xml EX-101.PRE 220257
38 EXTRACTED XBRL INSTANCE DOCUMENT ctic-20220331_htm.xml XML 422006
Mailing Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121
Business Address 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 2062827100
CTI BIOPHARMA CORP (Filer) CIK: 0000891293 (see all company filings)

IRS No.: 911533912 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-28386 | Film No.: 22918354
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences